The Canadian marijuana stocks we have weeded out have seen significant revenue growth over the past year
SmallCapPower | September 5, 2018: Today we have identified five Canadian marijuana stocks with market capitalization below $2B that have reported strong revenue growth during the past fiscal year. These Canadian cannabis stocks have already demonstrated strong operating cash flow ahead of the legalization of recreational cannabis in Canada on October 17, 2018.
Sunniva Inc. (CSE:SNN) – $6.73
Sunniva is a Canada-based producer of medical marijuana. The Company is vertically integrated with operations divided between production, clinics, and paraphernalia. SNN currently has more than 100,000 patients registered in its clinics. In June 2018, the Company’s subsidiary, CP Logistics LLC, secured a 12-month extraction services agreement with Cali Gold and Farmacy Phactory, two leading California cannabis brands. The Company is currently expanding its existing facility with a focus on expanding production yield to 200,000 kg/year by 2020. On August 29, 2018, the Company announced that its Q2/2018 revenue had increased by $1.2M when compared to Q2/2017.
- Market Cap: $215.6 Million
- Revenue Last Fiscal Year (CAD): $16,072,000
- Revenue Per Share (CAD): $0.64
CannTrust Holdings Inc. (TSX:TRST) – $10.39
CannTrust is a Canada-based licensed producer of medical cannabis. The Company’s products are sold online and delivered to registered patients. CannTrust’s Niagara production facility is 450,000 sq. ft. with a projected production of 100,000 kgs/year in 2019. The Company currently has a patent pending technology to enable cannabis infusion into beverage products. On July 11, CannTrust Holdings and Gold Coast University Hospital in Australia partnered for an ALS clinical trial.
- Market Cap: $1,073.7 Million
- Revenue Last Fiscal Year (CAD): $20,697,760
- Revenue Per Share (CAD): $0.26
Aleafia Health is a Canadian company focused on medical cannabis care through nationwide clinics, cultivation, and innovative research. Projected capacity for 2019 is estimated at 38,000 kg via a fully funded 337,000 sq. ft. production facility. On September 4, 2018 the Company received its sales license from Health Canada and reported Q2/2018 revenues of 1.2M.
- Market Cap: $141.9 Million
- Revenue Last Fiscal Year (CAD): $3,865,730
- Revenue Per Share (CAD): $0.11
CannaRoyalty Corp. (CSE:CRZ) – $6.25
CannaRoyalty is a Canada-based investor within the legal cannabis industry in the United States and Canada. The Company acts as a venture capital and management consulting platform that helps cannabis companies reach their full potential. It provides upfront capital to licensed cannabis businesses in exchange for a royalty on their revenues. The Company’s investments target prospects with promising R&D or IP, brand development and distribution. On August 23, 2018, the Company announced a record Q2/2018 revenue of $3.5M which represents a 265% increase from Q2/2017 revenues.
- Market Cap: $336.6 Million
- Revenue Last Fiscal Year (CAD): $3,077,970
- Revenue Per Share (CAD): $0.07
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: